CA3181945A1 - Hard capsule dosage form and uses thereof - Google Patents
Hard capsule dosage form and uses thereofInfo
- Publication number
- CA3181945A1 CA3181945A1 CA3181945A CA3181945A CA3181945A1 CA 3181945 A1 CA3181945 A1 CA 3181945A1 CA 3181945 A CA3181945 A CA 3181945A CA 3181945 A CA3181945 A CA 3181945A CA 3181945 A1 CA3181945 A1 CA 3181945A1
- Authority
- CA
- Canada
- Prior art keywords
- hydroxyvitamin
- dosage form
- formulation
- hard capsule
- calcifediol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032714P | 2020-05-31 | 2020-05-31 | |
| US63/032,714 | 2020-05-31 | ||
| PCT/IB2021/000220 WO2021205225A1 (en) | 2020-04-06 | 2021-04-06 | 25-hydroxyvitamin d for the treatment of sars-cov-2 infection |
| IBPCT/IB2021/000220 | 2021-04-06 | ||
| PCT/IB2021/000376 WO2021245458A1 (en) | 2020-05-31 | 2021-05-31 | Hard capsule dosage form and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3181945A1 true CA3181945A1 (en) | 2021-12-09 |
Family
ID=78831505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3181945A Pending CA3181945A1 (en) | 2020-05-31 | 2021-05-31 | Hard capsule dosage form and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230293552A1 (enExample) |
| EP (1) | EP4157231A1 (enExample) |
| JP (1) | JP2023526980A (enExample) |
| KR (1) | KR20230017192A (enExample) |
| CN (2) | CN115768412A (enExample) |
| AU (1) | AU2021285494A1 (enExample) |
| CA (1) | CA3181945A1 (enExample) |
| IL (1) | IL297885A (enExample) |
| WO (1) | WO2021245458A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245458A1 (en) * | 2020-05-31 | 2021-12-09 | Eirgen Pharma Ltd. | Hard capsule dosage form and uses thereof |
| WO2024063039A1 (ja) * | 2022-09-20 | 2024-03-28 | ロンザ株式会社 | 酸化マグネシウムを含有する遮光性ハードカプセル |
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264223A (en) | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5756123A (en) * | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
| FR2757173A1 (fr) | 1996-12-17 | 1998-06-19 | Warner Lambert Co | Compositions polymeres d'origine non-animale pour la formation de films |
| KR100379674B1 (ko) | 2000-03-06 | 2003-04-10 | 주식회사 서흥캅셀 | 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법 |
| CA2519208A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| CA2882048C (en) | 2006-02-03 | 2020-03-24 | Opko Renal, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| HUE037309T2 (hu) * | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
| RU2420538C2 (ru) * | 2006-10-27 | 2011-06-10 | Пфайзер Продактс Инк. | Жесткие капсулы из гидроксипропилметилцеллюлозы и способ их получения |
| ES2401205T3 (es) * | 2007-04-25 | 2013-04-17 | Cytochroma Inc. | Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo |
| CA2683514C (en) * | 2007-04-25 | 2019-07-09 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| PT2321273E (pt) * | 2008-07-24 | 2014-12-29 | Wisconsin Alumni Res Found | Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário |
| PL2480218T3 (pl) * | 2009-09-24 | 2020-11-16 | Capsugel Belgium Nv | Kapsułki odporne na kwas |
| KR20140072715A (ko) * | 2012-12-05 | 2014-06-13 | 삼성정밀화학 주식회사 | 경질 캡슐 |
| JP2014172850A (ja) * | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| EP4596045A3 (en) | 2016-03-28 | 2025-10-15 | EirGen Pharma Ltd. | Methods of vitamin d treatment |
| US12214084B2 (en) * | 2017-07-11 | 2025-02-04 | Qualicaps Co., Ltd. | Enteric hard capsule |
| WO2020044314A1 (en) | 2018-08-31 | 2020-03-05 | Opko Ireland Global Holdings, Ltd. | Vitamin d pediatric dosage forms, methods of making and using |
| US20210308151A1 (en) * | 2020-04-06 | 2021-10-07 | Eirgen Pharma Ltd. | Activating endogenous antimicrobials to treat sars-cov-2 infection |
| WO2021245458A1 (en) * | 2020-05-31 | 2021-12-09 | Eirgen Pharma Ltd. | Hard capsule dosage form and uses thereof |
-
2021
- 2021-05-31 WO PCT/IB2021/000376 patent/WO2021245458A1/en not_active Ceased
- 2021-05-31 EP EP21748934.3A patent/EP4157231A1/en active Pending
- 2021-05-31 AU AU2021285494A patent/AU2021285494A1/en active Pending
- 2021-05-31 CN CN202180038341.6A patent/CN115768412A/zh active Pending
- 2021-05-31 IL IL297885A patent/IL297885A/en unknown
- 2021-05-31 JP JP2022571817A patent/JP2023526980A/ja active Pending
- 2021-05-31 CA CA3181945A patent/CA3181945A1/en active Pending
- 2021-05-31 KR KR1020227041029A patent/KR20230017192A/ko active Pending
- 2021-05-31 CN CN202510867968.2A patent/CN120694962A/zh active Pending
- 2021-05-31 US US18/005,946 patent/US20230293552A1/en active Pending
-
2023
- 2023-05-18 US US18/199,117 patent/US20230330110A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021245458A1 (en) | 2021-12-09 |
| JP2023526980A (ja) | 2023-06-26 |
| EP4157231A1 (en) | 2023-04-05 |
| CN120694962A (zh) | 2025-09-26 |
| KR20230017192A (ko) | 2023-02-03 |
| CN115768412A (zh) | 2023-03-07 |
| IL297885A (en) | 2023-01-01 |
| AU2021285494A1 (en) | 2022-12-08 |
| US20230293552A1 (en) | 2023-09-21 |
| US20230330110A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230330110A1 (en) | Hard capsule dosage form and uses thereof | |
| ES2834900T3 (es) | Formulación de vitamina d de liberación modificada estabilizada y procedimiento de administración de la misma | |
| JP5894717B2 (ja) | 乱用抑止性製剤 | |
| JP6141583B2 (ja) | 濫用耐性製剤 | |
| JP2020180123A (ja) | デフェラシロクスの経口製剤 | |
| US20250025423A1 (en) | Pediatric dosage forms, methods of making and using | |
| JP5894720B2 (ja) | アルコール抵抗性製剤 | |
| JP2022081528A (ja) | ビタミンｄ治療法 | |
| KR20190122218A (ko) | 플로로글루시놀 및 트리메틸플로로글루시놀의 제약 제제 | |
| JP2013526523A (ja) | メトプロロールを含むアルコール耐性持続放出性経口剤形 | |
| JP6990470B2 (ja) | レナリドミド胃内滞留型徐放錠及びその調製方法 | |
| TWI645864B (zh) | 經穩定之修飾釋放維他命ｄ調配物及其服用方法 | |
| TWI812891B (zh) | 經穩定之修飾釋放維他命d調配物及其服用方法 | |
| TWI743426B (zh) | 經穩定之修飾釋放維他命d調配物及其服用方法 | |
| EA046180B1 (ru) | Фармацевтический состав флороглюцинола и триметилфлороглюцинола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250514 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250514 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250514 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250805 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250805 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250805 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250805 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260401 |